12.3 Hazardous Drug Handling & USP <800> Standards

12.3 Hazardous Drug Handling & USP <800> Standards

Healthcare personnel handling hazardous drugs face significant occupational health risks resulting from acute and chronic exposure to mutagenic, teratogenic, and carcinogenic chemical entities. Routine pharmacy tasks—such as unpacking shipments, counting tablets, reconstituting antineoplastics, and managing spills—can release hazardous dust, aerosols, and vapors that penetrate skin or mucous membranes. To establish comprehensive occupational safeguards, the United States Pharmacopeia promulgated USP General Chapter <800> (Hazardous Drugs – Handling in Healthcare Settings). In Utah, R156-17b-614e sets how USP <800> applies to compounding:

• Antineoplastic hazardous drugs (NIOSH list). On or before December 31, 2025, a pharmacy doing sterile or nonsterile compounding with antineoplastic HDs had to comply with USP <800>.
• Non-antineoplastic hazardous drugs. The pharmacy must compound in a double-HEPA-filtered or externally vented containment ventilated enclosure, a Class II biological safety cabinet, or a compounding aseptic containment isolator. A laminar airflow workbench or compounding aseptic isolator may be used when supported by a USP <800> assessment of risk. The pharmacy must clearly mark hazardous APIs and store them in a designated area separate from other drugs (a separate room is not required), and follow USP <800>, except listed sections such as facilities and engineering controls, environmental quality, spill control, and medical surveillance. It generally follows the documentation and SOP section, but need not do environmental wipe sampling or medical surveillance. Pharmacists, technicians, and health-system administrators must understand the chemical scope of hazardous drugs, risk assessment methodologies, containment engineering requirements, chemotherapy personal protective equipment (PPE), and decontamination procedures.

Scope of Hazardous Drugs & NIOSH Classification

USP <800> applies to all healthcare personnel who handle hazardous drug (HD) preparations and to all entities that store, prepare, transport, or administer HDs. The entity's list of HDs starts with the NIOSH List of Hazardous Drugs in Healthcare Settings. NIOSH identifies hazardous drugs by criteria such as carcinogenicity, developmental or reproductive toxicity, organ toxicity at low doses, genotoxicity, and structure and toxicity profiles that mimic existing hazardous drugs.

The NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (published December 2024) supersedes the 2016 list and its three groups. It now uses two tables:

• Table 1: Drugs that have manufacturer's special handling information (MSHI) in the package insert, and/or meet the NIOSH definition and are classified as known or probable human carcinogens (NTP or IARC Group 1 or 2A). Most antineoplastics are here (e.g., cisplatin, cyclophosphamide, fluorouracil, methotrexate, doxorubicin, tamoxifen, vincristine), along with drugs such as azathioprine and cyclosporine.
• Table 2: Drugs that meet the NIOSH definition but are not in Table 1 (e.g., spironolactone, carbamazepine, tacrolimus, divalproex). A column flags drugs whose only hazard is developmental and/or reproductive (e.g., finasteride, dutasteride, ribavirin, mifepristone, oxytocin, fluconazole, clonazepam).

Utah's rule (R156-17b-614e) still separates antineoplastic HDs, which require full USP <800> compliance, from non-antineoplastic HDs, which follow Utah's modified requirements.

Assessment of Risk (AoR)

Every healthcare entity must maintain a list of hazardous drugs it handles and review it at least every 12 months. Instead of applying every USP <800> containment requirement, an entity may perform a documented Assessment of Risk (AoR) for:

• Antineoplastic HDs that only require counting or packaging of final dosage forms (such as counting intact methotrexate tablets); and
• Final dosage forms of non-antineoplastic HDs, including those that are only reproductive hazards (such as finasteride).
• Not eligible under USP <800>: any HD active pharmaceutical ingredient (API), and any antineoplastic HD that requires manipulation beyond counting or packaging (such as crushing tablets or compounding). These must follow all USP <800> containment requirements.

---

Containment Engineering Controls (C-PECs, C-SECs & CSTDs)

Handling hazardous drugs requires specialized containment ventilation systems to prevent active chemical molecules from circulating into staff work areas or escaping into the environment:

Containment Primary Engineering Controls (C-PECs)

The C-PEC is the ventilated containment hood designed to minimize worker exposure:

• For Non-Sterile HD Compounding: May use a Class I Biological Safety Cabinet (BSC), a Class II BSC, or a Containment Compounding Aseptic Isolator (C-CAI). The C-PEC must be externally vented (preferred) or have redundant HEPA filters in series. A containment ventilated enclosure (CVE) may also be used.
• For Sterile HD Compounding: Must use a Class II BSC or a compounding aseptic containment isolator (CACI). Must achieve ISO Class 5 air quality, provide unidirectional vertical downward airflow, and must be 100% externally vented to the outside of the building. Recirculating the exhaust into the room is not allowed for sterile HD compounding.
• Room pressure, not hood pressure: The -0.01 to -0.03 inch water column specification applies to the rooms (C-SEC or C-SCA) that house the C-PEC, not to the C-PEC itself.

Containment Secondary Engineering Controls (C-SECs)

The C-SEC is the specialized room that encloses the C-PEC:

• Sterile HD Cleanroom Suite (Buffer Room): Must achieve ISO Class 7 air cleanliness, maintain continuous negative pressure between -0.01 and -0.03 inches of water column relative to adjacent areas, be externally vented to the outdoors, and provide a minimum of 30 Air Changes Per Hour (ACPH).
• Anteroom for Sterile HD Cleanroom: Because the buffer room is negative, the anteroom must meet the elevated standard of ISO Class 7 (not ISO Class 8) to prevent air contamination, maintain positive pressure relative to general corridors, and supply a minimum of 30 ACPH.
• Non-Sterile HD Compounding Room: Must maintain continuous negative pressure (-0.01 to -0.03 inches water column), be externally vented, and provide a minimum of 12 ACPH.
• Containment Segregated Compounding Area (C-SCA): An unclassified negative-pressure room (-0.01 to -0.03" w.c.) with external venting and at least 12 ACPH. Sterile HDs prepared in a C-SCA are Category 1 CSPs (BUD ≤12 hours room temp or ≤24 hours refrigerated).

Closed System Drug-Transfer Devices (CSTDs)

A CSTD is a drug-transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system. Under USP <800>:

• CSTDs are recommended during compounding.
• CSTDs are strictly mandatory during administration of antineoplastic hazardous drugs when the dosage form allows (e.g., attaching an IV line to an infusion port).

---

Personal Protective Equipment (PPE) Standards

USP <800> establishes strict chemical-barrier standards for all personnel handling hazardous drugs:

1. Chemotherapy Gloves: Must be tested and certified to ASTM Standard D6978 (which tests permeation resistance against chemotherapy drugs). Standard medical exam or surgical gloves are strictly prohibited. Two pairs of chemotherapy gloves are mandatory for compounding (sterile and non-sterile), administering injectables, cleaning C-PECs, and managing spills. The inner glove is worn under the gown cuff, while the outer glove is worn over the cuff. Outer gloves must be changed every 30 minutes (or immediately if torn, punctured, or contaminated).
2. Chemotherapy Gowns: Must be disposable, lint-free, low-permeability (polyethylene-coated or laminated material), close in the back, and feature long sleeves with snug knit or elastic cuffs. Gowns must be changed every 2 to 3 hours (or immediately if splashed, contaminated, or compromised). Gowns worn in HD areas must never be worn outside the HD containment space.
3. Respiratory Protection: Surgical masks provide no respiratory protection. A fit-tested NIOSH-certified N95 or more protective respirator protects against airborne particles but not gases or vapors. Personnel unpacking HDs that are not contained in plastic should wear an elastomeric half-mask with a multi-gas cartridge and P100 filter until packaging integrity is confirmed. A full-facepiece chemical cartridge-type respirator or a PAPR is needed for spills larger than a spill kit can contain, for deactivating and cleaning underneath the C-PEC work surface, and for known or suspected airborne exposure to powders or vapors.
4. Eye and Face Protection: When there is a risk of splashing or aerosol generation (e.g., cleaning hoods, managing spills), personnel must wear chemical splash goggles and a full-face shield. Eyeglasses or safety glasses with side shields do not adequately protect against splashes.
5. Shoe Covers: Two pairs of shoe covers are required when compounding hazardous drugs. The outer shoe covers must be removed and discarded in a chemotherapy waste receptacle before stepping out of the negative-pressure buffer room into the anteroom.

---

Receiving, Storage, Cleaning & Spill Management

Safe Receiving and Storage

• Receiving & Unpacking: Hazardous drugs must be unpacked in an area with neutral or normal pressure or negative pressure (such as an HD storage room). They must never be unpacked in positive-pressure sterile cleanrooms. Personnel unpacking HDs must wear chemotherapy gloves. The entity's SOPs must say how damaged shipping containers are handled.
• Storage Requirements: Antineoplastic HDs requiring manipulation must be stored in a dedicated, externally vented, negative-pressure room with at least 12 ACPH, completely segregated from non-hazardous inventory. Dedicated HD refrigerators must be located in a negative-pressure room (at least 12 ACPH). Hazardous drugs must not be stored on the floor. Under Utah's rule, a hazardous non-antineoplastic API may instead be stored in a designated area separate from other drugs, without a separate room (R156-17b-614e(4)(b)).

The Four-Step Surface Maintenance Protocol

Surfaces within C-PECs and secondary containment areas must be routinely cleaned using an unyielding four-step protocol executed in precise order:

1. Deactivation: Chemically renders the hazardous drug inert or inactive. Common agents include oxidizing agents such as sodium hypochlorite or peroxide formulations.
2. Decontamination: Inactivates, neutralizes, or physically removes hazardous drug residues from the surface. Involves wiping down surfaces with sterile water, alcohol, or dedicated neutralizers. (Bleach must be followed by sterile water or sodium thiosulfate to prevent pitting and corrosion of stainless steel surfaces).
3. Cleaning: Physically removes organic and inorganic soil and microbial debris using a germicidal detergent.
4. Disinfection: Inhibits or destroys microorganisms. Mandatory for sterile compounding areas; accomplished using sterile 70% isopropyl alcohol (IPA) applied after the cleaning step.

Loading diagram...

Spill Management & Dedicated Equipment

• Spill Kits: Fully stocked hazardous drug spill kits must be readily accessible in every location where HDs are stored, transported, compounded, or administered. Spill kits typically contain two pairs of chemo gloves, safety goggles, an N95 or elastomeric respirator, absorbent chemo pads, neutralizing powder, disposable scoops, and hazardous waste disposal bags.
• Dedicated Equipment: Counting trays, spatulas, mortars, pestles, and stirring equipment used for hazardous drugs should be dedicated to HDs, clearly labeled, and decontaminated after each use. A counting tray used for finasteride or methotrexate should not be used for non-hazardous drugs like penicillin or amoxicillin.

---

Common MPJE Traps & Scenario Analysis

1. The Positive-Pressure Chemo Trap: A hospital administrator proposes installing a biological safety cabinet inside an existing positive-pressure IV cleanroom to prepare chemotherapy. Exam Trap: Compounding hazardous drugs in a positive-pressure room forces hazardous aerosols into adjacent hallways and staff workrooms. Sterile HD cleanrooms must operate under continuous negative pressure (-0.01 to -0.03" w.c.) with 100% external venting.
2. Assessment of Risk for Bulk Chemicals: A compounding pharmacy drafts an Assessment of Risk (AoR) to skip USP <800> containment for methotrexate bulk powder. Exam Trap: USP <800> never allows an AoR for an HD API, and Utah requires full USP <800> compliance for antineoplastic HD compounding. (For non-antineoplastic APIs such as spironolactone, Utah's R156-17b-614e sets its own, less restrictive containment requirements.)
3. Surgical Mask Adequacy: A technician dons a standard pleated surgical mask to clean up a large hazardous drug spill. Exam Trap: Surgical masks provide no respiratory protection. A spill larger than a spill kit can contain calls for a full-facepiece chemical cartridge-type respirator or a PAPR.
4. Anteroom Air Classification for HDs: An exam scenario states that an anteroom opening into a negative-pressure chemotherapy buffer room meets ISO Class 8 standards. Exam Trap: When connecting to a negative-pressure buffer room, the anteroom must achieve the cleaner standard of ISO Class 7 to prevent ingress of unclassified air.